Janelle Fauci
Experienced in Salpingo-Oophorectomy

Dr. Janelle Fauci

Oncology
125 Queens Road, Suite 540, 
Charlotte, NC 
Offers Telehealth
19 Years of Experience
Experienced in Salpingo-Oophorectomy
125 Queens Road, Suite 540, 
Charlotte, NC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Janelle Fauci is an Oncologist in Charlotte, North Carolina. Dr. Fauci has been practicing medicine for over 19 years and is rated as an Experienced provider by MediFind in Salpingo-Oophorectomy. Her top areas of expertise are Vulvar Cancer, Endometrial Cancer, Ovarian Cancer, Ovarian Carcinosarcoma, and Salpingo-Oophorectomy.

Her clinical research consists of co-authoring 15 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Salpingo-Oophorectomy.

Graduate Institution
University Of South Florida College Of Medicine, 2007.0
Residency
UAB Hospital
Specialties
Oncology
Licenses
Obstetrics & Gynecology in NC
Board Certifications
Gynecologic Oncology
Hospital Affiliations
Novant Health Mint Hill Medical Center
Novant Health Huntersville Medical Center
Novant Health Presbyterian Medical Center
Novant Health Matthews Medical Center
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Absolute Total Care South Carolina
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

Novant Health Cancer Institute - Elizabeth (Gynecologic Oncology)
125 Queens Road, Suite 540, Charlotte, NC 28204

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer. A Multi-Arm Trial for Women With Recurrent or Persistent Endometrial Cancer
A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer. A Multi-Arm Trial for Women With Recurrent or Persistent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 03, 2025
Intervention Type: Drug, Procedure, Biological
Study Phase: Phase 2
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 02, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Atezolizumab, Bevacizumab, Pegylated liposomal doxorubicin hydrochloride
Study Phase: Phase 2/Phase 3
A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 13, 2025
Intervention Type: Drug
Study Drugs: Niraparib, Dostarlimab
Study Phase: Phase 3
View 2 Less Clinical Trials

15 Total Publications

Dostarlimab and niraparib in primary advanced ovarian cancer.
Dostarlimab and niraparib in primary advanced ovarian cancer.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: April 11, 2025
Similar Doctors
Kellie Schneider
Experienced in Salpingo-Oophorectomy
Dr. Kellie Schneider
Oncology
Experienced in Salpingo-Oophorectomy
Dr. Kellie Schneider
Oncology

Novant Health Cancer Institute - Elizabeth (Gynecologic Oncology)

125 Queens Road, Suite 540, 
Charlotte, NC 
 (0.1 miles away)
980-302-6560
Experience:
22+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Kellie Schneider is an Oncologist in Charlotte, North Carolina. Dr. Schneider has been practicing medicine for over 22 years and is rated as a Distinguished provider by MediFind in Salpingo-Oophorectomy. Her top areas of expertise are Endometrial Cancer, Ovarian Carcinosarcoma, Sertoli-Leydig Cell Tumor, Salpingo-Oophorectomy, and Splenectomy.

Jubilee Brown
Experienced in Salpingo-Oophorectomy
Dr. Jubilee Brown
Oncology
Experienced in Salpingo-Oophorectomy
Dr. Jubilee Brown
Oncology

Atrium Health Levine Cancer Institute (Gynecologic Cancer)

1021 Morehead Medical Drive, Suite 2100, 
Charlotte, NC 
 (0.9 miles away)
980-442-2000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jubilee Brown is an Oncologist in Charlotte, North Carolina. Dr. Brown is rated as a Distinguished provider by MediFind in Salpingo-Oophorectomy. Her top areas of expertise are Endometrial Cancer, Ovarian Cancer, Sertoli-Leydig Cell Tumor, Endoscopy, and Tubal Ligation. Dr. Brown is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Fauci's expertise for a condition
ConditionClose
    View All 7 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile